Opus Genetics Inc
Opus Genetics Inc (IRD) Covered Calls
Opus Genetics Inc trades in the Biotechnology industry with an IV Rank of 87.70%, high versus the past year. IRD's highest covered call setup is the $5.00 strike expiring Feb 19, 2027, sorted by theoretical annualized return. It's 25.31% out of the money with 91 days to expiration, a 31.58% return until expiration, and a 126.66% theoretical annualized return. Across the setups shown, annualized returns run from 126.66% to 126.66% at strikes between $5.00 and $5.00, with 91 days to expiration, as of Nov 20, 2026.
Read more
Running IRD covered calls helps you generate income from Opus Genetics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best IRD covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If IRD stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling IRD covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given IRD covered call is worth writing.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
| 2027-02-19 | 91 | 5.00 | 25.31 | 0.25 | 1.25 | 126.00 | 31.58 | 126.66 | -6.27 | +0.51 | 4,516 | 1.00 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank87.70% High
- Market cap (M$)386
- 52 weeks high-43.56%
- 52 weeks low114.52%
- Analyst recommendationStrong Buy
1.00 - Target price$13.94
249.37% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-1.59
- EPS growth next 5 years29.14%
As of Nov 20, 2026